metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)
versus lapatinib plus capecitabine
	trastuzumab emtansine
	EMILIA, 2012 N Engl J Med 2012;367:1783-91 Lancet Oncol 2017; 18: 732–42 NCT00829166	RCT	la/mBC - HER2 positive - 2nd Line (L2)	trastuzumab emtansine	lapatinib plus capecitabine	patients with HER2-positive unresectable, locally advanced or metastatic breast cancer, who had previously been treated with trastuzumab and a taxane.	495 / 496	some concern	conclusif	demonstrated 32 % decrease in deaths (OS) (PE) demonstrated 35 % decrease in progression or deaths (PFS) (PE) suggested 25 % decrease in deaths (OS) (extension) demonstrated 73 % increase in objective responses (ORR) (PE)
versus trastuzumab emtansine
	trastuzumab deruxtecan
	DESTINY Breast03, 2022 N Engl J Med 2022 Mar 24;386(12):1143-1154. NCT03529110	RCT	la/mBC - HER2 positive - 2nd Line (L2)	trastuzumab deruxtecan	trastuzumab emtansine	patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane	-/-	some concern	suggested	suggested 45 % decrease in deaths (OS) suggested 72 % decrease in progression or deaths (PFS)